Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Author: Editor
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy. Read here: https://meetinglibrary.asco.org/record/190814/abstract
Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy. Read here: https://meetinglibrary.asco.org/record/190814/abstract
Peter Adamson, MD of Sanofi discusses the FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. All three abstracts were presented at this year’s virtual ASCO. Ziopharm will present updated clinical data from its Phase 1/2 controlled IL-12 program. Data will show clinical results of its IL-12 gene therapy, Ad+V, as a monotherapy and in combination with nivolumab for the treatment of recurrent glioblastoma (rGBM). Phase 1 data from this program have shown that treatment with Ad+V can double the median overall survival of patients with rGBM.
Hatem Soliman, MD of Moffitt Cancer Center @MoffittResearch discusses at the 12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy. Read here: https://meetinglibrary.asco.org/record/190814/abstract
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses DARolutamide observationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients. Read her: https://meetinglibrary.asco.org/record/191738/abstract
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here:Â https://meetinglibrary.asco.org/record/191796/abstract
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here:Â https://meetinglibrary.asco.org/record/191796/abstract
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): MAIC. Read here:Â https://meetinglibrary.asco.org/record/188306/abstract
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): MAIC. Read here:Â https://meetinglibrary.asco.org/record/188306/abstract
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here:Â https://meetinglibrary.asco.org/record/187482/abstract
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here:Â https://meetinglibrary.asco.org/record/187482/abstract
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer presented at this year’s virtual ASCO. Read here:Â https://meetinglibrary.asco.org/record/187482/abstract
Cynthia X. Ma, MD of Washington University School of Medicine @WUSTLmed discusses neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women.
Cynthia X. Ma, MD of Washington University School of Medicine @WUSTLmed discusses neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women.
Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study presented at this year’s virtual ASCO. Read here:Â https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA4
Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study presented at this year’s virtual ASCO. Read here:Â https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA4
Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition. More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html
Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition. More here: https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html
Brigitte C. Widemann, MD and Andrea Gross, MD of National Cancer Institute discuss selumetinib, the first medicine approved to treat paediatric patients with neurofibromatosis type 1 plexiform neurofibromas, a rare and debilitating genetic condition. More here:Â https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html
Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from the COVID-19 and Cancer Consortium (CCC19). Read here: https://meetinglibrary.asco.org/record/191968/abstract
Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from the COVID-19 and Cancer Consortium (CCC19). Read here:Â https://meetinglibrary.asco.org/record/191968/abstract
Jeremy Warner, MD of Vanderbilt-Ingram Cancer Center @VUMC_Cancer discusses the clinical impact of COVID-19 on patients with cancer: data from the COVID-19 and Cancer Consortium (CCC19). Read here:Â https://meetinglibrary.asco.org/record/191968/abstract
Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast cancer patients. https://meetinglibrary.asco.org/record/190666/abstract
Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast cancer patients. https://meetinglibrary.asco.org/record/190666/abstract
Daniel Vorobiof, MD of Belong.Life @Belong_Life discusses real-world data of physician’s advice on BRCA genetic testing for ovary and breast cancer patients. https://meetinglibrary.asco.org/record/190666/abstract
Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression after the next line of therapy following pembrolizumab or P plus chemotherapy vs EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma. Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6505
Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression after the next line of therapy following pembrolizumab or P plus chemotherapy vs EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma. Read here:Â https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6505
Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression after the next line of therapy following pembrolizumab or P plus chemotherapy vs EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma. Read here:Â https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6505
Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here:Â https://meetinglibrary.asco.org/record/191881/abstract
Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here:Â https://meetinglibrary.asco.org/record/191881/abstract
Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here:https://meetinglibrary.asco.org/record/191881/abstract
Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer. Read here:Â https://meetinglibrary.asco.org/record/191881/abstract
Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer. Read here: https://meetinglibrary.asco.org/record/191745/abstract
Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer. Read here: https://meetinglibrary.asco.org/record/191745/abstract
Jennifer Crozier, MD of Baptist Health @BaptistHealthSA discusses the FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer. Read here:Â https://meetinglibrary.asco.org/record/191745/abstract
Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor. Read here: https://investors.deciphera.com/news-releases/news-release-details/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm
Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor. Read here: https://investors.deciphera.com/news-releases/news-release-details/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm
Margaret von Mehren, MD of Fox Chase Cancer Center @FoxChaseCancer discusses the FDA Full Approval of Deciphera Pharmaceuticals’ QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor. Read here: https://investors.deciphera.com/news-releases/news-release-details/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm
Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: a randomized controlled trial. Read here:Â https://meetinglibrary.asco.org/record/186710/abstract
Daneng Li, MD @DanengLi of City of Hope @cityofhope on geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: a randomized controlled trial. Read here:Â https://meetinglibrary.asco.org/record/186710/abstract
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community.In this video, Dr. Li shares information on the role of immunotherapy for unresectable stage 3 non small cell lung cancer.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent clinical care.
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent clinical care.
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent clinical care. Read here:Â https://meetinglibrary.asco.org/record/185972/abstract
Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC). Read here: https://meetinglibrary.asco.org/record/186053/abstract
Earn CME: https://www.naccme.com/program/20-hemcovid-7 In this webcast, Drs. Joseph R. Mikhael and Michael J. Satlin discuss new updates on the current understanding of the epidemiology and pathology of SARS-CoV-2 and outlines current treatment strategies, including the potential for interactions with anticancer agents. © 2020 Imedex, an HMP Company
Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC). Read here:Â https://meetinglibrary.asco.org/record/186053/abstract